Finch Therapeutics Group (FNCH) Competitors $12.40 0.00 (0.00%) As of 09/16/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsShort InterestTrendsBuy This Stock FNCH vs. IRD, BYSI, ASRT, CNTX, PMVP, UNCY, IGMS, RPTX, IZTC, and ELYMShould you be buying Finch Therapeutics Group stock or one of its competitors? The main competitors of Finch Therapeutics Group include Opus Genetics (IRD), BeyondSpring (BYSI), Assertio (ASRT), Context Therapeutics (CNTX), PMV Pharmaceuticals (PMVP), Unicycive Therapeutics (UNCY), IGM Biosciences (IGMS), Repare Therapeutics (RPTX), Invizyne Technologies (IZTC), and Eliem Therapeutics (ELYM). These companies are all part of the "pharmaceutical products" industry. Finch Therapeutics Group vs. Its Competitors Opus Genetics BeyondSpring Assertio Context Therapeutics PMV Pharmaceuticals Unicycive Therapeutics IGM Biosciences Repare Therapeutics Invizyne Technologies Eliem Therapeutics Finch Therapeutics Group (NASDAQ:FNCH) and Opus Genetics (NASDAQ:IRD) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, media sentiment, valuation, dividends, profitability, analyst recommendations and institutional ownership. Do institutionals & insiders believe in FNCH or IRD? 21.8% of Finch Therapeutics Group shares are owned by institutional investors. Comparatively, 15.0% of Opus Genetics shares are owned by institutional investors. 44.9% of Finch Therapeutics Group shares are owned by company insiders. Comparatively, 6.6% of Opus Genetics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts prefer FNCH or IRD? Opus Genetics has a consensus price target of $7.33, indicating a potential upside of 414.62%. Given Opus Genetics' stronger consensus rating and higher probable upside, analysts clearly believe Opus Genetics is more favorable than Finch Therapeutics Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Finch Therapeutics Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Opus Genetics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, FNCH or IRD? Finch Therapeutics Group has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500. Comparatively, Opus Genetics has a beta of 0.07, meaning that its stock price is 93% less volatile than the S&P 500. Does the media prefer FNCH or IRD? In the previous week, Opus Genetics had 2 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 3 mentions for Opus Genetics and 1 mentions for Finch Therapeutics Group. Finch Therapeutics Group's average media sentiment score of 1.00 beat Opus Genetics' score of 0.90 indicating that Finch Therapeutics Group is being referred to more favorably in the media. Company Overall Sentiment Finch Therapeutics Group Positive Opus Genetics Positive Which has stronger valuation and earnings, FNCH or IRD? Opus Genetics has higher revenue and earnings than Finch Therapeutics Group. Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFinch Therapeutics GroupN/AN/A-$74.75M-$8.82-1.41Opus Genetics$10.99M7.77-$57.53M-$1.92-0.74 Is FNCH or IRD more profitable? Finch Therapeutics Group has a net margin of 0.00% compared to Opus Genetics' net margin of -377.89%. Finch Therapeutics Group's return on equity of -69.14% beat Opus Genetics' return on equity.Company Net Margins Return on Equity Return on Assets Finch Therapeutics GroupN/A -69.14% -26.92% Opus Genetics -377.89%-384.33%-148.90% SummaryOpus Genetics beats Finch Therapeutics Group on 8 of the 15 factors compared between the two stocks. Get Finch Therapeutics Group News Delivered to You Automatically Sign up to receive the latest news and ratings for FNCH and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FNCH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FNCH vs. The Competition Export to ExcelMetricFinch Therapeutics GroupBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.91M$291.42M$5.73B$10.23BDividend YieldN/AN/A5.88%4.63%P/E Ratio-1.41N/A77.0326.39Price / SalesN/A422.15527.21121.53Price / CashN/A22.4437.2060.52Price / Book0.8710.3313.936.32Net Income-$74.75M-$111.61M$3.30B$271.37M7 Day Performance-2.13%0.77%0.87%2.18%1 Month Performance-2.36%6.16%4.60%6.81%1 Year Performance7.83%-14.40%84.43%27.75% Finch Therapeutics Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FNCHFinch Therapeutics Group1.3828 of 5 stars$12.40flatN/A+7.8%$19.91MN/A-1.41190Positive NewsShort Interest ↓IRDOpus Genetics2.423 of 5 stars$1.34-1.5%$7.33+447.3%N/A$80.28M$10.99M-0.7014Gap UpBYSIBeyondSpringN/A$1.98+1.9%N/A-12.8%$79.70MN/A0.0080News CoverageGap DownASRTAssertio1.7393 of 5 stars$0.80+0.5%$2.38+195.8%-32.3%$77.28M$117.10M-1.7820News CoverageGap UpCNTXContext Therapeutics3.7586 of 5 stars$0.86+1.1%$5.25+514.0%-59.2%$76.96MN/A-2.387Positive NewsPMVPPMV Pharmaceuticals2.8804 of 5 stars$1.44-10.3%$5.50+283.3%-20.0%$76.73MN/A-0.9250Gap UpHigh Trading VolumeUNCYUnicycive Therapeutics2.325 of 5 stars$4.35-0.8%$60.00+1,280.9%+6.3%$76.64M$680K-1.059Analyst ForecastIGMSIGM Biosciences2.7526 of 5 stars$1.27flat$4.89+285.0%N/A$76.57M$145.05M-1.41190RPTXRepare Therapeutics3.025 of 5 stars$1.74+0.6%$4.50+158.6%-47.6%$74.75M$250K-0.67180Positive NewsIZTCInvizyne TechnologiesN/A$11.76-2.0%N/AN/A$73.52MN/A0.0029ELYMEliem TherapeuticsN/A$2.47+3.3%N/A-75.2%$73.49MN/A-4.669 Related Companies and Tools Related Companies IRD Alternatives BYSI Alternatives ASRT Alternatives CNTX Alternatives PMVP Alternatives UNCY Alternatives IGMS Alternatives RPTX Alternatives IZTC Alternatives ELYM Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FNCH) was last updated on 9/17/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Finch Therapeutics Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Finch Therapeutics Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FNCH Stock Alerts